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Abstract
Background: Although timely treatment of COPD exacerbations seems clinically important, nearly half of these
exacerbations remain unreported and subsequently untreated. Recent studies have investigated incidence and
impact of failure to seek medical treatment during exacerbations. Yet, little is known about type and timing of
other self-management actions in periods of symptom deterioration. The current prospective study aims at
determining the relative incidence, timing and determinants of three types of patient responses.
Methods: In a multicentre observational study, 121 patients (age 67 ± 11 years, FEV1pred. 48 ± 19) were followed
for 6 weeks by daily diary symptom recording. Three types of action were assessed daily: planning periods of rest,
breathing techniques and/or sputum clearing (type-A), increased bronchodilator use (type-B) and contacting a
healthcare provider (type-C).
Results: Type-A action was taken in 70.7%, type-B in 62.7% and type C in 17.3% of exacerbations (n = 75). Smokers
were less likely to take type-A and B actions. Type-C actions were associated with more severe airflow limitation
and increased number of hospital admissions in the last year.
Conclusions: Our study shows that most patients are willing to take timely self-management actions during
exacerbations. Future research is needed to determine whether the low incidence of contacting a healthcare
provider is due to a lack of self-management or healthcare accessibility.
Background
Chronic obstructive pulmonary disease (COPD) is char-
acterised by a progressive decline in respiratory function,
exercise capacity and health status [1]. This underlying
disease state is interrupted by episodes of acute worsen-
ing in respiratory symptoms. If these deteriorations are
beyond individual day-to-day variability, these are defined
as exacerbations [2]. It is widely recognized that acute
exacerbations play a central role in COPD-related mor-
bidity and mortality [1]. Exacerbations are associated
with marked physiologic deterioration that may affect
disease progression by accelerating reductions in forced
expiratory volume in 1 s (FEV1) [3,4], have a significant
negative effect on the individual’s health-related quality
of life (HRQoL) [5,6] and generate an increasing burden
on health services and economic costs [7]. Several studies
have shown that almost 50% of exacerbations remain
unreported and subsequently do not receive adequate
treatment [8-10]. Although unreported exacerbations are
often considered to be mild, recent studies have shown
that these exacerbations may have short and long term
consequences on patients health-related quality of life
[9,10]. Moreover, early treatment and thus early recogni-
tion of exacerbation symptoms has shown to improve
outcome of exacerbations [11]. In addition, patients who
refrain from seeking treatment during these episodes or
have less self-management capacity show higher hospita-
lization rates compared to those who seek early treat-
ment from physicians or have better self-management
capacity [12].
Until now, little is known why exacerbations remain
unreported except that they seem shorter in length, dis-
play less shortness of breath and are less associated with
cough [9,13]. To improve the understanding on delay
and failure to seek medical treatment, more knowledge is
needed on exacerbation perception and health behaviour
by patients specifically during exacerbation episodes.
This knowledge can give a more profound direction in
approaches aiming at increasing exacerbation related
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[14].
The current observational study aims at a prospective
evaluation of the hypothesis that whilst not contacting a
healthcare provider in the event of an exacerbation,
patients might take other types of self-management
action. More specifically, the objectives of the study were:
(1) to determine the relative incidence of different types
of action taken by patients in the event of an exacerba-
tion, (2) to determine the time patients take to act in the
event of an exacerbation and (3) to compare characteris-
tics of patients according to those who take or do not
take timely action measures.
Methods
Patients
Between January and March 2008, COPD patients were
recruited from inpatient (post-discharge) and outpatient
clinics from the University Medical Hospital in Utrecht, 6
peripheral hospitals and 5 general practices. Patients were
followed during a period of 6 weeks (42 days). Patients
required the following criteria (extracted from chart
review): 1) aged over 40 years; 2) primarily diagnosis of
COPD; 3) complaints of dyspnea and/or chronic cough
with or without hypersecretion; 4) history of smoking
(> 20 years of smoking or > 15 packyears); 5) post-bronch-
odilator FEV/FVC of ≤ 0,7 according to the global initia-
tive for chronic obstructive lung disease (GOLD)
standards [1]. Patients were excluded if they had a primary
diagnosis of asthma, cardiac disease or any medical condi-
tion other than COPD with functional limitation. Ethical
approval was obtained from the Medical-Ethical Review
Committee (METC) of the UMC Utrecht, and all patients
gave their written informed consent prior to inclusion.
Study Design
This is an observational study with a prospective evalua-
tion of patient daily decision in the event of an exacerba-
tion. Data were obtained from a pilot-study aiming at the
development of an Action Plan for COPD patients. At
recruitment, patients were asked to record respiratory
symptom deteriorations on a daily basis, using a diary card
[15]. Patients were instructed to fill in this diary at a fixed
moment of the day; i.e. after evening diner. The diary card
consisted of major symptoms (dyspnea, sputum volume
and sputum color), and minor symptoms (sore throat,
fever, cough, common cold, wheezing). Major symptoms
were scored when an increase was perceived. Minor symp-
toms were scored when they were present that day, and
not part of the patients’ normal symptom status. In addi-
tion, patients were instructed to note whether they con-
tacted a healthcare provider, increased their inhalation
medication, started a course of corticosteroids or antibio-
tics or increased their attention on planning periods of
rest, breathing techniques and sputum expectoration.
Patients were contacted by the investigators by telephone
after the first 7 days to review their compliance and under-
standing with regard to the daily assessments. Patients did
not receive any additional written or verbal self-manage-
ment instructions on how to act in the event of an
exacerbation.
After completion of the study period, patients’ records
were examined for baseline and healthcare utilization data
(visits to the physician, the emergency department and
hospital from the medical records). Self-reported health-
care contacts were matched with contacts extracted from
the medical records and subsequently the exact date was
ascertained. Charlson’s comorbidity index (comorbidities
extracted from chart review) was used to determine the
degree of comorbidity [16]. This index is based on relative
risks of mortality, in which 19 conditions are assigned
with values of 1, 2, 3, or 6 (all other conditions are given a
score of 0). The weights were then summed for each
patient.
Exacerbations
A symptom-based exacerbation was confirmed if, for at
least two consecutive days, patients experienced a worsen-
ing of at least one of three major symptoms (increased
sputum amount, changed sputum color/purulence, and
increased dyspnea) [9,10,17]. Severity of exacerbation was
divided in type 1, 2 and 3, with addition of a type 4, by
definition of Vijayasaratha et al. [18]. A type 1 exacerba-
tion included an increase in three major symptoms, a type
2 exacerbation was defined as an increase in two major
symptoms, a type 3 exacerbation was defined as an
increase in one major and at least one minor symptom,
and a type 4 exacerbation when only 1 major symptom
was increased without the addition of any minor symp-
toms. Daily symptoms were binary coded and summed to
give a daily symptom count. Major symptoms are scored
as: normal = 0; small increase = 1; or clear increase = 2.
The minor symptoms were scored 0 and 1, respectively.
The sum of these scores resulted in a daily symptom
count ranging from 0-11 points. Exacerbation onset was
taken as the first day on which these symptom criteria
were met. As a second estimation of exacerbation severity,
the number of individual increased symptoms was
counted up in a minor, major and total symptom count.
All first exacerbations were taken into account, provided
that at least three consecutive major symptom free days
were counted before exacerbation onset. Exacerbation
recovery was regarded as the first of three consecutive
major symptom free days (back to baseline or new level of
stability).
Symptomatic days
Symptomatic days were defined as separated days with
increased minor or major symptoms, preceded by at
least three consecutive days without symptom change.
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were not part of an exacerbation episode.
Measurement of actions taken by patients
Three types of action measures were evaluated. Selection
of these actions was made according to a large multina-
tional interview-based study in which patients were asked
to retrospectively report on exacerbation experiences
[19]. These actions were operationally defined as types:
A) increased attention on planning periods of rest,
breathing techniques and/or sputum expectoration; B)
increasing the use of inhaled medication from the regular
dial in the normal dose of inhalation medication. Type C
actions were defined as contacting (telephone consulta-
tion or visit) a healthcare provider.
Statistical analysis
All patients that returned their diaries were included in
analysis. Statistical analysis was performed using SPSS ver-
sion 14.01. Normally distributed data are presented as
mean (SD) and otherwise as median (interquartile range;
IQR). Incidence and timing of the three different types of
actions were evaluated between three days before to ten
days after exacerbation onset. To compare characteristics
of patients who take or do not take timely action mea-
sures, differences in patient, event and system characteris-
tics were tested by Chi-squared test, Mann-Whitney
U-test or Student t-test depending on the level of
measurement. A p-value of < 0.05 was considered to be
statistically significant.
Results
A total of 203 COPD patients were asked to participate in
the study (Figure 1). Of these, a total number of 141 (69%)
patients were enrolled in the study of which 20 (14%) were
lost to follow up, leaving 121 patients (86%) eligible for
analysis. Patients lost to-follow did not significantly differ
in terms of baseline characteristics. Thirteen patients (9%)
returned an incompletely filled in diary. To prevent selec-
tive loss to follow up, these diaries were included in the
analysis.
Table 1 shows the baseline characteristics of the
included patients. The patients were recruited from
scheduled outpatient clinic visits (68.6%), scheduled gen-
eral physician visits (11.6%) and patients at discharge
after hospital admission for treatment of an exacerbation
( 1 9 . 8 % ) .A b o u t6 0 %o ft h ep a t i e n t sw e r em a l ea n dt h e
average age was 67 years. Patient had on average moder-
ate to severe COPD (FEV1%pred: 47.7 ± 18.5) and 23.1%
were smoking at the time of enrolment. Comorbidity
scored according to the Charlson’si n d e xw a sl o w .T h e
121 diaries contained 5082 diary cards, of which 238 (5%)
were missing. The number of missing diary days ranged
f r o m4t o3 2d a y s .T h em e a nt o t a lt i m es p e n ti nt h e
study was 40.03 (± 5.74) days.
During the observational period 75 first exacerbations
were observed of which 26 (35%) were severity type 1,
20 (27%) type 2, 19 (25.%) type 3, and 10 (13.%) exacer-
bations were defined as type 4. At exacerbation onset,
most patients reported an increase in dyspnea (81%) and
increased cough (51%). Furthermore, 27% of exacerbat-
ing patients reported increased amounts of sputum and
28% reported a change in sputum purulence.
Symptomatic days
We analyzed 979 symptomatic days (not part of an exacer-
bation and preceded by at least three consecutive stable
days). A total of 926 (95%) symptomatic days had an
increase in one or more minor symptoms, from which a
majority of 874 (89%) days were not accompanied by an
increase in one or more major symptoms. A total of 86
(9%) symptomatic days had an increase in one major symp-
tom, 14 (1,4%) had an increase in two major symptoms,
and 1 (0.1%) had an increase in three major symptoms. No
data on action measures was available on 4 (0.4%) days.
Actions taken by patients
Figure 2 shows the incidence and cumulative incidence and
timing of actions initiated between three days before to ten
days after exacerbation onset. The majority of patients
experiencing an exacerbation performed type-A (70.7%)
and type-B actions (62.7%), while only 17.3% of the exacer-
bations were followed by type-C actions. Type-A actions
were mainly taken in the days prior to onset (median -3,
IQR -3 to 0), while type-B actions were taken at onset
(median 0 IQR -1 to 1). Timing of the 17.3% of patients
taking type-C actions did not show a clear pattern (median
4 IQR 0.5 to 5.5) in proportion to exacerbation onset.
Table 2 shows patient-, and exacerbation characteristics
for the different actions taken. Taking type-A actions was
significantly more often performed by non-smoking
patients (20.8% vs 42.9%, p = 0.04). Patients taking type A
actions had significantly longer duration of exacerbations;
10.4 (95%CI 8.7-12.2) vs 6.5 (95%CI 3.6-8.6) days, p =
0.04). Smokers were also less likely to take type-B actions
(17.4% vs 43.9%, p = 0.02). Initiation of type-B actions was
significantly associated with dyspnea at onset of the
exacerbation (89.4% vs 67.9%, p = 0.02). The opposite was
seen when exacerbation symptoms at onset included
increased sputum purulence (19.1% vs 42.9%, p = 0.03).
Taking type-C actions was significantly associated with
more severe airflow obstruction; 35.5 (95%CI 27.4-40.8) vs
45.8 (95%CI 41.4-50.2) %pred, p = 0.04) and increased
mean number of hospital admissions in the previous year;
1.9 (95%CI 1.5-2.3) vs 0,6 (95%CI 0.4-0.8), p = 0.001).
Actions on symptomatic days
Figure 3 shows actions taken on symptomatic days, not
part of an exacerbation. From the 874 symptomatic days
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associated with type-A actions, 201 (23.0%) with type-B
and 12 (1.4%) with type-C actions. For symptomatic
days with an increase in at least one major symptom
(n = 101), these numbers are respectively 43 (42.6%), 29
(28.7%) and 2 (2.0%). In a small proportion of stable
days, i.e.with no symptom increase, nevertheless type-A
actions were initiated (17,1%). In 5,2% and 0,6% of these
stable days patients performed type-B and type-C
actions respectively.
Discussion
The results of this study demonstrate that despite the
high amount of unreported exacerbations, most COPD
patients do recognize periods of symptom deteriorations
and are willing to take certain self-management actions.
To our knowledge, this is the first prospective study
investigating patient’s decisions and self-management
behaviour during symptomatic days and exacerbation
episodes.
It is well established that COPD exacerbations have
clear negative impact on disease progression, morbidity,
mortality, and HRQoL [3,5,20]. According to current
guidelines, exacerbations should be treated with
increased bronchodilator therapy, glucocorticosteroids
and/or antibiotics [1]. Patient recognition of exacerba-
tion of symptoms and prompt intervention reduces the
risk of hospitalisation and is associated with a better
Figure 1 Flow chart of participants through the study.
Table 1 Baseline characteristics of all patients and patients with and without at least one symptom based
exacerbations
Characteristics All patients No symptom-based exacerbation At least one symptom-based exacerbation
Number of patients 121 46 75
Sex, male 74 (61.2) 27 (58.7) 47 (62.7)
Age, yr 67.4 ± 10.5 68.6 ± 11.3 66.6 ± 9.9
FEV1 1.29 ± 0.58 1.42 ± 0.68 1.20 ± 0.50
§
FEV1 % predicted 47.7 ± 18.5 53.7 ± 18.6 44.0 ± 17.6
┼
Charlson’s comorbidity index score 1 [0-2] 1 [0-2] 1 [0-2]
Current smoking 28 (23.1) 8 (17.4) 20 (27.0)
Recruitment
Scheduled outpatient clinic visit 83 (86.6) 30 (36.1) 53 (63.9)
Scheduled general physician visit 14 (11.6) 5 (35.7) 9 (64.3)
Discharge from hospital admission 24 (19.8) 11 (45.8) 13 (54.2)
Hospital admissions 1yr prior to study
-0 68 (56.2) 25 (54.3) 43 (57.3)
-1 32 (26.4) 15 (32.6) 17 (22.7)
-2 or more 21 (17.4) 6 (13.1) 15 (20.0)
Home oxygen therapy 12 (9.9) 5 (10.9) 7 (9.3)
Data are expressed as mean ± SD, median [IQR] or count (percentage).
§ p < 0.05;
┼p < 0.01.
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different cohort studies have revealed that only a minor-
ity of exacerbations in fact are reported and subse-
quently treated [8-10]. Despite the fact that reported
exacerbations have on average the worst outcomes,
unreported exacerbations showed in a Canadian and a
Chinese cohort to have important and non-negligible
impact on annual change in health status [9,10] Until
now, only a few studies examined potential determinants
of reporting exacerbations. Delay or failure to report
exacerbations seems to be associated with a combination
of disease, event and patient characteristics. Our study
also confirmed that patients with more severe airflow
limitation and higher hospitalisation rates in the pre-
vious year are more likely to report an exacerbation
[9,22]. In a Canadian cohort, a higher number of symp-
toms at onset and exacerbations with increased cough
and sputum quantity were associated with reporting [9].
In addition, other studies show that psychological char-
acteristics may also be considered as potential predictors
of seeking medical treatment [10,23,24].
In contrast to the lack of seeking medical attention,
patients did seem to recognize consistent warning signs
stimulating them to anticipate on these episodes. Rather
than contacting a healthcare provider, the majority
( 7 0 . 7 % )o fp a t i e n t ss h o w e dawillingness to increase
their attention on planning periods of rest, breathing
techniques and/or sputum expectoration. A similar high
proportion of patients increased their bronchodilation
medication (62.7%). These findings are in line with two
multinational interview-based studies investigating
patients perceptions of retrospectively self-reported
exacerbations [13,19]. These studies also showed that
the majority of COPD patients are able to recognize and
respond to periods of symptom deterioration. Only one
study reported on exacerbation-related actions focused
on planning periods of rest (30% rest; 10% lie/sit down;,
10% stay calm/prepare) [19]. Furthermore both studies
found that 33% of the patients anticipated by increasing
medication [13,19]. It needs to be emphasized that com-
parisons partly hampers both because of differences in
operational definition of an exacerbation and the meth-
ods used to assess these self-management actions.
In the current study, both type-A and type-B actions
were conducted timely, mainly during prodrome and at
exacerbation onset. The latter is consistent with findings
of a previous study reporting that half of the exacerba-
tions were related to self-initiated use of rescue medica-
tion, mainly during the week before reporting the
exacerbation [22]. Obviously, patients cannot predict
whether prodromal days with symptom increase turn
into actual exacerbations. This was reflected by examin-
ing actions during isolated symptomatic days that were
not part of an exacerbation. Around 40% of these days
were also associated with type-A actions and 25% with
type-B actions. This suggests that a substantial amount
of patients seem to respond immediately to symptom
changes, even if this only concerns increase in minor
symptoms.
In addition to reporting of exacerbations, we related
patient characteristics for timely taken type-A and type-B
action measures during exacerbations. Interestingly for
both types of action, current smoking had an increased
likelihood of been associated with less appropriate self-
management actions. Similar defaults in self-management
behaviour by current smokers were seen from previous
studies in using appropriately meter dose inhaler techni-
que [25], being adherent to long term nebulizer therapy
[26] and attending outpatient pulmonary rehabilitation
[27,28]. Furthermore, correct type-A actions were more
frequently taken in patients with longer exacerbations epi-
sodes. Finally, the type of symptoms showed to influence
Figure 2 Incidence and cumulative incidence of three type of action measures performed in the event of an exacerbation.
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Page 5 of 9Table 2 Characteristics of patients taking or not taking timely action measures
Planning periods of rest,
breathing techniques, and
sputum expectoration
Increased
inhalation
medication
Contact with
healthcare
provider
yes no p yes no p yes no p
N 53 (70.7) 22 (29.3) 47 (62.7) 28 (37.3) 13 (17.3) 62 (82.7)
Patient
characteristics
Sex, male 34 (64.2) 13 (59.1) 0.68 28 (59.6) 19 (67.9) 0.47 10 (76.9) 37 (59.7) 0.24
Age 66.8 (66.1-71.5) 66.2 (62.1-
70.3)
0.80 67.4 (67.4-70.3) 65.4 (61.8-69.0) 0.39 63.0 (57.2-68.8) 67.4 (64.9-69.8) 0.15
Living alone 35 (66.0) 14 (67) 0.96 32 (68.1) 17 (63) 0.65 6 (46) 43 (71) 0.09
FEV1-%pred 41.7 (38.4-44.0) 49.8 (41.5-
58.1)
0.07 43.3 (38.0-48.6) 45.3 (39.4-51.2) 0.63 35.5 (27.5-40.8) 45.8 (41.4-50.2) 0.04*
Current smoking 11 (20.8) 9 (42.9) 0.04* 8 (17.4) 12 (43.9) 0.02 2 (15.4) 17 (27.9) 0.35
Hospital admissions in previous year 1.0 (0.6-1.4) 0.4 (0.1-0.7) 0.07 1.0 (0.6-1.4) 0.5 (0.2-0.8) 0.09 1.9 (1.5-2.3) 0.6 (0.4-0.8) 0.001**
Charlson’s comorbidity score 1 0 [1,2] 1 0 [1,2] 0.85 1 0 [1,2] 1 [0-1.8] 0.42 1 [0-2.5] 1 0 [1,2] 0.99
Event
characteristics
Episode length, days 10.4 (8.7-12.2) 6.5 (3.6-8.6) 0.04* 10.2 (8.0-12.4) 7.8 (5.1-10.5) 0.20 11.6 (7.5 -15.7) 8.8 (6.9-10.7) 0.22
Severity 0.32 0.31 0.42
- Anth. I
- Anth. II
- Anth. III
- Anth. IV
21 (39.6)
15 (28.3)
11 (20.8)
6 (11.3)
5 (22.7)
5 (22.7)
8(36.4)
4 (7.6)
16 (34.0)
10 (21.3)
15 (31.9)
6(12.8)
10 (35.7)
10 (35.7)
4(14.3)
4(14.3)
6 (46.1)
4(30.8)
3(23.1)
0(0.0)
20 (32.3)
16 (25.8)
16 (25.8)
10 (16.1)
Symptom count at onset 2.7 (2.3-3.1) 2.2 (1.7-2.7) 0.16 2.5 (2.1-2.9) 2.6 (2.1-3.2) 0.72 2.7 (2.0-3.4) 2.5 (2.2-2.9) 0.66
Major symptoms at day 1
- dyspnea
- sput purulence
- sput volume
43 (81.1)
17 (32.1)
15 (28.3)
18 (81.8)
4 (18.2)
5 (22.7)
0.95
0.22
0.62
42 (89.4)
9 (19.1)
10 (21.3)
19 (67.9)
12 (42.9)
10 (35.7)
0.02†
0.03†
0.17
10 (76.9)
5 (38.5)
3(23.1)
51 (82.3)
16 (25.8)
17 (27.4)
0.65
0.35
0.75
Data are expressed as Mean (95%CI), Median [Interquartile range] or count (percentage).
FEV1-% pred: Forced Expiratory Volume in 1 second-percentage of the predicted value; Anth: Anthonissen;
*p≤ 0.05 Student T-test, ** p ≤ 0.01 Student T-Test, † p ≤ 0.05 Chi-square test
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9patients’ self-management decisions during exacerbations.
Patients perceiving increased dyspnea at exacerbation
onset are more likely to take type-B actions that patients
without increased dyspnea. Patients with increased sputum
purulence are less likely than patients without increased
sputum purulence to take action. We believe this study
provides valuable new insights in how patient respond to
symptom deterioriation. This knowledge can support the
development of improved patient information and mate-
rial to enhance appropriate self-management of exacerba-
tions. However, a few words of caution are needed when
interpreting the results. First, although this study was the
first to examine self-management decisions prospectively,
it comprised a relatively small group of 108 consecutive
patients followed up for only 6 weeks resulting in 75
exacerbations. This is equal to an annual rate of 6.0 per
patient-year This relatively high event-rate can be
explained by the fact that all patients were simultaneously
followed-up in the same 6-week winter period in which
exacerbations have shown to be ~ 50% more likely than in
other seasons [6,29]. Also the relative high proportion of
patients included immediately after hospitalisation might
have contributed to a higher exacerbation rate.
Secondly, the relatively short period of follow-up only
allowed for the evaluation of a single exacerbation per
patient. Data from a well-known UK cohort indicates
that exacerbations, although not validated in terms of
aetiology, are not random events but clustered in time
[30]. The fact that we did not evaluate multiple exacerba-
tion episodes per patient, could have resulted in biased
and incomplete judgment of relapsed or recurrent
exacerbations and subsequently the presence or absence
of correct self-management behavior. A longer follow-up
would have created the opportunity to judge within-
patient variations over time, taking into account cluster-
ing of exacerbations. A stable run-in period of at least 4
weeks could have eliminated recurrent exacerbations
[30].
Thirdly, another limiting factor is that after dichoto-
mizing episodes by actions carried out, the number of
events per predictor variable did not reach the rule of
thumb to allow for multivariate logistic regression analy-
sis [31]. Therefore, the present study solely evaluated the
association between single characteristics and actions
taken. Adequately powered observational studies allowing
multivariate analysis including adjustment for potential
confounders are needed to validate current indicators of
self-management behaviour.
This study was not designed and powered to examine
the effects of different self-management decisions taken by
patients on exacerbation related outcome (recovery time,
severity etc). Nevertheless, indirectly from the literature, it
can be expected that early and self-initiated response on
these episodes including all three type of actions most
likely affect outcome. Self-management measures during
periods of symptom deterioration like changing activity,
relaxation, and breathing pattern alteration, a proxy for
type-A actions, have shown to be effective in faster symp-
tom relief [32,33]. Furthermore, there is sufficient evidence
that prompt anticipation by increasing short-acting
bronchodilators (type-B actions) is effective in reducing
symptoms and improve airflow obstruction during exacer-
bations [1,34]. Our study indicates that a substantial
amount of exacerbations remain partly or completely
unmanaged. As recommended, these results stress the
importance of developing and investigating individualized
therapies specifically aiming at early recognition and con-
sequent actions to these episodes by patients [35]. Within
Figure 3 Actions performed on symptomatic days not part of an exacerbations episode.
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tion concerning exacerbation-related health behavior
should go out to current smokers.
Conclusion
This study provides new and important data on deci-
sion-making and self-management behaviour during
periods of symptom deterioration and exacerbations in
patients with COPD. It shows that the majority of
patients with COPD are willing to respond promptly
when confronted with these acute episodes, but gener-
ally refrain from reporting to a healthcare provider.
These findings have increased the understanding of
patient’s perception of exacerbations and predisposal
factors of poor self-management. Furthermore, it contri-
butes to the development and effective targeting of
exacerbation related self-management interventions.
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